Key Segments:
By Dosage Strength
- 60 mg Tablets
- 90 mg Tablets
- Others (Any special strengths, combination formulations, or investigational doses)
By Indication
- Acute Coronary Syndrome (ACS)
- Myocardial Infarction (MI) Prevention
- Percutaneous Coronary Intervention (PCI)
- Others (Stroke prevention in high-risk cardiovascular patients, peripheral arterial disease)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Specialty cardiac clinics, government tenders, and institutional supply)
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others (Research organizations, rehabilitation centers)
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
The global ticagrelor market is expected to reach USD 3.60 billion by 2035, growing from USD 1.80 billion in 2025.
The market is projected to grow at a CAGR of 7.18% over the forecast period from 2026 to 2035.
Key drivers include the rising prevalence of cardiovascular diseases, increasing PCI procedures, growing use of dual antiplatelet therapy, and expanding healthcare infrastructure in emerging economies.
North America leads the global market due to advanced healthcare infrastructure, high cardiovascular treatment rates, and strong adoption of antiplatelet therapies.
The 90 mg tablets segment holds the largest market share, accounting for 54.21% in 2025, as it is widely used in the initial treatment of acute coronary syndrome patients.
Get in touch
